Rubius Therapeutics to Participate at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

Get Alerts RUBY Hot Sheet

Price: $0.08 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate at the following investor conferences:

Fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference, Thursday, February 28, 2019, at 10:30 a.m. ET in New York, NY
Presentation at Cowen and Company’s 39th Annual Health Care Conference, Tuesday, March 12, 2019, at 10:40 a.m. ET in Boston, MA

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following each event. About Rubius TherapeuticsRubius Therapeutics is a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines. The Company’s proprietary RED PLATFORM® is designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent allogeneic cellular therapies. Rubius is leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction for the potential treatment of rare enzyme disorders, cancer and autoimmune diseases. The Company expects to file an Investigational New Drug application during the first quarter of 2019, for its lead program RTX-134 for the treatment of phenylketonuria. For more information, visit www.rubiustx.com or follow us on Twitter and LinkedIn.

Contacts:Lori MelançonVice President, Corporate Communications and Investor Relations+1 (617) 949-5296[email protected]

Media Contact: Dan Budwick1AB+1 (973) 271-6085[email protected]